Assess Particle Deposition and Acute Effects of Symbicort® Forte Turbohaler®) in COPD Patients.

Chronic Obstructive Pulmonary Disease Clinical Trial

Official title:

A Randomized, Double-blind, Placebo-controlled, Two Way Cross-over Study to Assess the Particle Deposition and Acute Effects of Formoterol and Budesonide Combination Therapy (Symbicort® Forte Turbohaler®) on the Upper Airway Dimensions in COPD Patients.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01329276
• Other study ID #: PML_DOC_0905_/_ISSSYMB0020
• Secondary ID: 2009-016502-16
• Status: Completed
• Phase: Phase 4
• First received: March 30, 2011
• Last updated: April 1, 2011
• Start date: June 2010
• Est. completion date: January 2011

Study information

• Verified date: March 2011
• Source: University Hospital, Antwerp
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federal Agency for Medicinal Products and Health Products
• Study type: Interventional

Clinical Trial Summary

Computational Fluid Dynamics (CFD) is a new functional imaging method. Since CFD is very sensitive to detect small changes, it might be worthwhile to study the acute effect of formoterol and budesonide combination therapy (Symbicort® forte Turbohaler®) on the upper airway dimensions in severe COPD patients (GOLD III). The increased sensitivity of this technique makes it possible to detect changes in airway caliber in early stages. The regional distribution of resistance and the change in this parameter will provide more insight into the mode of action of the product.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: January 2011
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

1. Patients with documented COPD based on the following criteria:

Smoking history of at least 10 pack-years and decreased Tiffeneau index (FEV1/(F)VC < 0.70).

2. Patients should present severe COPD with an FEV1 between 50 and 30% of predicted (GOLD 3).

3. Male or female patients aged = 40 years.

4. Patients should be treated according to GOLD guidelines before study start.

5. Patients with, in the opinion of the investigator, a co-operative attitude and ability to be trained to correctly use the TurbohalerR.

6. Maintained on stable respiratory medications for 6 weeks prior to visit 1.

7. Written informed consent obtained.

Exclusion Criteria:

1. Pregnancy, breast-feeding or planned pregnancy during the study. Fertile women not using acceptable contraceptive measures, as judged by the investigator.

2. Inability to carry out pulmonary function testing.

3. A respiratory infection or exacerbation of COPD in the four weeks prior to screening.

4. Any significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the results of the study, or the patient's ability to participate in the study

5. A history of asthma, cystic fibrosis, central bronchiectasis, interstitial lung disease or pulmonary thromboembolic disease.

6. Cancer or any other chronic disease with poor prognosis and/or affecting patient status.

7. A history of thoracotomy with pulmonary resection.

8. Allergy, sensitivity or intolerance to study drugs and/or study drug formulation ingredients.

9. History of alcohol or drug abuse.

10. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.

11. Patients who received any investigational new drug within the last 4 weeks prior to the screening visit.

12. Patients treated with any non-permitted concomitant medication (see 7.2).

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Chronic Obstructive Pulmonary Disease
• Lung Diseases, Obstructive
• Pulmonary Disease, Chronic Obstructive

Intervention

Drug:
• Symbicort® forte Turbohaler®
320 µg budesonide / 9 µg formoterol fumarate dihydrate

Locations

Country	Name	City	State
Belgium	University Hospital Antwerp	Edegem (Antwerp)	Antwerp

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Antwerp	AstraZeneca

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	total airway resistance	To evaluate the effect of the combination therapy on the upper airway dimensions and to assess the particle deposition with Computational Fluid Dynamics (CFD). The parameters that will be obtained with CFD and used as primary outcome variables are total airway resistance and total airway volume.		No
Primary	total airway volume	To evaluate the effect of the combination therapy on the upper airway dimensions and to assess the particle deposition with Computational Fluid Dynamics (CFD). The parameters that will be obtained with CFD and used as primary outcome variables are total airway resistance and total airway volume.		No
Secondary	effect of formoterol and budesonide combination therapy on lung function	The secondary objective of this study is to assess the effect of formoterol and budesonide combination therapy on lung function (spirometry, body plethysmography and resistance).		No